

OFFICE OF THE SECRETARY OF STATE

LAVONNE GRIFFIN-VALADE
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE
AND TRIBAL LIAISON



ARCHIVES DIVISION

STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

PERMANENT ADMINISTRATIVE ORDER

BP 51-2024

CHAPTER 855

BOARD OF PHARMACY

FILED

06/18/2024 8:42 AM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Repeals Div 020 Protocol Compendium

EFFECTIVE DATE: 06/20/2024

AGENCY APPROVED DATE: 06/13/2024

CONTACT: Rachel Melvin

971-673-0001

pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150

Portland, OR 97232

Filed By:

Rachel Melvin

Rules Coordinator

REPEAL: 855-020-0300

REPEAL: Temporary 855-020-0300 from BP 1-2024

NOTICE FILED DATE: 04/17/2024

RULE SUMMARY: Permanently repeals OAR 855-020-0300 Protocol Compendium. The board adopted Division 115 Pharmacists rules effective 3/1/2024 which replace Division 020. OAR 855-115-0345 includes current versions of the protocols.

CHANGES TO RULE:

~~855-020-0300~~

~~Protocol Compendium~~

~~A Pharmacist may prescribe, via statewide drug therapy management protocol and according to rules outlined in this Division, an FDA-approved drug and device listed in the following compendium:¶¶~~

~~(1) Continuation of therapy including emergency refills of insulin (v. 06/2023);¶¶~~

~~(2) Conditions¶¶~~

~~(a) Cough and cold symptom management¶¶~~

~~(A) Pseudoephedrine (v. 06/2021);¶¶~~

~~(B) Benzonatate (v. 06/2021);¶¶~~

~~(C) Short-acting beta agonists (v. 06/2021);¶¶~~

~~(D) Intranasal corticosteroids (v. 06/2021);¶¶~~

~~(b) Vulvovaginal candidiasis (VVC) (v. 06/2021);¶¶~~

~~(c) COVID-19 Antigen Self-Test (v. 12/2021);¶¶~~

~~(3) Preventative care¶¶~~

~~(a) Emergency Contraception (v. 06/2021);¶¶~~

~~(b) Male and female condoms (v. 06/2021);¶¶~~

~~(c) Tobacco Cessation, Nicotine Replacement Therapy (NRT) and Non-NRT (v. 06/2022);¶¶~~

~~(d) Travel Medications (v. 06/2023);¶¶~~

~~(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);¶¶~~

~~(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 06/2023);¶¶~~

~~(g) Contraception (v. 06/2023); and¶¶~~

~~(h) Vaccinations:¶¶~~

~~(A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 2/2024);¶¶~~

- (B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 2/2024); ¶¶
- (C) Cholera (v. 2/2024); ¶¶
- (D) Coronavirus 2019 (v. 2/2024); ¶¶
- (E) Haemophilus Influenza type b (v. 2/2024)¶¶
- (F) Hepatitis A containing vaccines (v. 2/2024); ¶¶
- (G) Hepatitis B containing vaccines (v. 2/2024); ¶¶
- (H) Human Papillomavirus (v. 2/2024); ¶¶
- (I) Influenza – Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2023-24 (v. 2/2024); ¶¶
- (J) Influenza – Live Attenuated Influenza Vaccine 2023-24 (v. 2/2024); ¶¶
- (K) Japanese Encephalitis (v. 2/2024); ¶¶
- (L) Meningococcal containing vaccines (v. 2/2024); ¶¶
- (M) Measles Mumps & Rubella containing vaccines (v. 2/2024); ¶¶
- (N) Pneumococcal (v. 2/2024); ¶¶
- (O) Polio (v. 2/2024); ¶¶
- (P) Rabies (v. 2/2024); ¶¶
- (Q) Respiratory Syncytial Virus (v. 2/2024); ¶¶
- (R) Tetanus Diphtheria containing vaccines (v. 2/2024); ¶¶
- (S) Typhoid (v. 2/2024); ¶¶
- (T) Varicella containing vaccines (v. 2/2024); ¶¶
- (U) Yellow fever (v. 2/2024); ¶¶
- (V) Zoster (v. 2/2024).¶¶

[Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.696